Piper Jaffray Cos. set a $41.00 price target on Cellectis SA (NASDAQ:CLLS) in a report released on Thursday morning. The brokerage currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on the company. Jefferies Group reissued a buy rating on shares of Cellectis SA in a research note on Friday, August 5th. Oppenheimer Holdings Inc. reaffirmed an outperform rating and set a $65.00 target price on shares of Cellectis SA in a research note on Wednesday, September 14th. Finally, Zacks Investment Research raised Cellectis SA from a hold rating to a buy rating and set a $21.00 target price for the company in a research note on Thursday, October 20th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Cellectis SA presently has an average rating of Buy and a consensus price target of $42.33.

Cellectis SA (NASDAQ:CLLS) traded up 3.68% on Thursday, hitting $18.05. 92,198 shares of the stock were exchanged. The company’s 50-day moving average is $18.85 and its 200-day moving average is $25.20. Cellectis SA has a 52 week low of $16.35 and a 52 week high of $34.99.

COPYRIGHT VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/25/cellectis-sa-clls-given-a-41-00-price-target-at-piper-jaffray-cos.html.

Several institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC raised its position in Cellectis SA by 6,025.1% in the second quarter. Perceptive Advisors LLC now owns 183,507 shares of the company’s stock worth $4,879,000 after buying an additional 180,511 shares during the period. Taube Hodson Stonex Partners LLP raised its position in Cellectis SA by 58.6% in the second quarter. Taube Hodson Stonex Partners LLP now owns 269,776 shares of the company’s stock worth $7,173,000 after buying an additional 99,664 shares during the period. Morgan Stanley raised its position in Cellectis SA by 1,034.6% in the third quarter. Morgan Stanley now owns 64,817 shares of the company’s stock worth $1,561,000 after buying an additional 59,104 shares during the period. Baker BROS. Advisors LP bought a new position in Cellectis SA during the third quarter worth $1,204,000. Finally, GAM Holding AG raised its position in Cellectis SA by 258.5% in the third quarter. GAM Holding AG now owns 54,570 shares of the company’s stock worth $1,314,000 after buying an additional 39,350 shares during the period. Institutional investors and hedge funds own 20.02% of the company’s stock.

About Cellectis SA

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

5 Day Chart for NASDAQ:CLLS

Receive News & Stock Ratings for Cellectis SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis SA and related stocks with our FREE daily email newsletter.